特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
939921

画像診断分野での提携:2014年~2020年までの世界的な契約の条件

Global Diagnostic Imaging Partnering Terms and Agreements 2014 to 2020

出版日: | 発行: Current Partnering, a division of Wildwood Ventures Limited | ページ情報: 英文 350+ Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
画像診断分野での提携:2014年~2020年までの世界的な契約の条件
出版日: 2020年06月01日
発行: Current Partnering, a division of Wildwood Ventures Limited
ページ情報: 英文 350+ Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートは、2014年から2020年の世界の画像診断分野における提携について調査したもので、契約締結のトレンド、財務面の条件、主な契約と関連組織、契約文書の要覧、技術タイプ別の契約などの情報を提供しています。

目次

エグゼクティブサマリー

第1章 - イントロダクション

第2章 -契約のトレンド

  • イントロダクション
  • 長期的な提携
  • 活発な動きのあるメーカー
  • 契約タイプ別の提携
  • 治療分野別の提携
  • 契約条件
    • 主な金額
    • 先行支払
    • マイルストーンペイメント
    • ライセンス料

第3章 -主な契約

  • イントロダクション
  • 金額の大きな契約

第4章 -活発な動きのある組織

  • イントロダクション
  • 契約に向け活発に動いている組織
  • 提携に積極的な企業のプロファイル

第5章 -契約文書要覧

  • イントロダクション
  • 契約文書要覧

第6章 -技術タイプ別の契約

第7章 パートナリングリソースセンター

  • オンラインパートナリング
  • パートナリングイベント
  • 契約締結に関する資料

付録

目次
Product Code: CP21041

‘The Global Diagnostic Imaging Partnering Terms and Agreements 2014 to 2020 report’ provides comprehensive understanding and unprecedented access to the diagnostic imaging partnering deals and agreements entered into by the worlds leading healthcare companies.

‘The Global Diagnostic Imaging Partnering Terms and Agreements 2014 to 2020 report’ provides comprehensive understanding and unprecedented access to the diagnostic imaging partnering agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter diagnostic imaging partnering deals. This report provides details of the latest diagnostics agreements announced in the healthcare sectors, covering:

  • Imaging
  • CT
  • Endoscope
  • Molecular and nuclear
  • PET
  • SPECT
  • MRI
  • Ultrasound
  • X ray
  • Angiography
  • Fluoroscopy
  • Mammography

This report provides an overview of diagnostic imaging dealmaking, the common clauses, rights and options in the partnering agreement, and also a comprehensive review of deals signed in since 2014.

This report provides a comprehensive and detailed review of all diagnostic imaging deals announced since 2014. The comprehensive agreements chapter is organized by company A-Z, stage of development at signing, deal type, and therapy focus. Each deal title links via Weblink to an online version of the actual deal at Current Agreements (www.currentagreements.com) deals and alliances database, providing easy access to each deal on demand. Where available, the full deal contract document is also provided and indicated by a document symbol.

Contract documents provide unsurpassed access to the detail of a deal normally announced in brief summary through a press release. Detailed analysis of a contract allow better understanding of the terms agreed between the parties, and importantly the basis under which monies and licensing rights are exchanged.

The initial chapters of this report provide an orientation of Diagnostic Imaging dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Diagnostic Imaging dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Diagnostic Imaging deals since 2014. Deals are listed by headline value, signed by big pharma, most active Diagnostic Imaging dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Diagnostic Imaging dealmaking with a brief summary followed by a comprehensive listing of Diagnostic Imaging deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Diagnostic Imaging partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Diagnostic Imaging partnering deals signed and announced since Jan 2014. The chapter is organized by specific Diagnostic Imaging technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Diagnostic Imaging partnering company A-Z, deal type definitions and Diagnostic Imaging partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Diagnostic Imaging partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Diagnostic Imaging technologies and products.

Key benefits

‘Global Diagnostic Imaging Partnering Terms and Agreements’ provides the reader with the following key benefits:

  • In-depth understanding of diagnostic deal trends since 2014
  • Analysis of the structure of diagnostic agreements with numerous real life case studies
  • Comprehensive access to over 600 actual diagnostic imaging deals entered into by the world's biopharma companies
  • Detailed access to actual diagnostic contracts enter into by the leading biopharma companies
  • Insight into the terms included in a diagnostic agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

‘Global Diagnostic Imaging Partnering Terms and Agreements’ is intended to provide the reader with an in-depth understanding of the diagnostic imaging trends and structure of deals entered into by leading companies worldwide.

‘Global Diagnostic Imaging Partnering Terms and Agreements’ includes:

  • Trends in diagnostic imaging dealmaking in the biopharma industry since 2014
  • Analysis of diagnostic imaging deal structure
  • Case studies of real-life diagnostic imaging deals
  • Access to over 600 diagnostic imaging contract documents
  • The leading diagnostic imaging deals by value since 2014
  • Most active diagnostic imaging dealmakers since 2014
  • The leading diagnostic imaging partnering resources

In ‘Global Diagnostic Imaging Partnering Terms and Agreements’, the available contracts are listed by:

  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Specific technology target

Each deal title links to online deal records of actual diagnostic imaging partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The ‘Global Diagnostic Imaging Partnering Terms and Agreements’ report provides comprehensive access to available contract documents for over 600 diagnostic imaging deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise diagnostic rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

The ‘Global Diagnostic Imaging Partnering Terms and Agreements 2014 to 2020’ provides the reader with the following key benefits:

  • In-depth understanding of diagnostic imaging deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of diagnostic imaging agreements with numerous real life case studies
  • Comprehensive access to over 600 actual diagnostic imaging deals entered into by the world's biopharma companies, together with contract documents if available
  • Detailed access to actual diagnostic imaging contracts entered into by themost active companies
  • Identify leading diagnostic imaging deals by value since 2014
  • Identify the most active diagnostic imaging dealmakers since 2014
  • Insight into the terms included in a diagnostic imaging agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Diagnostic Imaging dealmaking

  • 2.1. Introduction
  • 2.2. Diagnostic Imaging partnering over the years
  • 2.3. Most active Diagnostic Imaging dealmakers
  • 2.4. Diagnostic Imaging partnering by deal type
  • 2.5. Diagnostic Imaging partnering by therapy area
  • 2.6. Deal terms for Diagnostic Imaging partnering
    • 2.6.1 Diagnostic Imaging partnering headline values
    • 2.6.2 Diagnostic Imaging deal upfront payments
    • 2.6.3 Diagnostic Imaging deal milestone payments
    • 2.6.4 Diagnostic Imaging royalty rates

Chapter 3 - Leading Diagnostic Imaging deals

  • 3.1. Introduction
  • 3.2. Top Diagnostic Imaging deals by value

Chapter 4 - Most active Diagnostic Imaging dealmakers

  • 4.1. Introduction
  • 4.2. Most active Diagnostic Imaging dealmakers
  • 4.3. Most active Diagnostic Imaging partnering company profiles

Chapter 5 - Diagnostic Imaging contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Diagnostic Imaging contracts dealmaking directory

Chapter 6 - Diagnostic Imaging dealmaking by technology type

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Diagnostic Imaging deals by company A-Z
  • Appendix 2 - Diagnostic Imaging deals by stage of development
  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Regulatory
  • Marketed
  • Formulation
  • Appendix 3 - Diagnostic Imaging deals by deal type
  • Asset purchase
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Co-promotion
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Litigation
  • Manufacturing
  • Manufacturing - OEM
  • Marketing
  • Option
  • Promotion
  • Research
  • Settlement
  • Spin out
  • Sub-license
  • Supply
  • Technology transfer
  • Termination
  • Appendix 4 - Diagnostic Imaging deals by therapy area
  • Breast
  • Cardiovascular
  • Central Nervous System
  • Dental
  • Dermatology
  • Gastrointestinal
  • Genetic disorders
  • Genitourinary
  • Gynaecology
  • Hematology
  • Hospital care
  • Immunology
  • Infectives
  • Musculoskeletal
  • Obstetrics
  • Oncology
  • Ophthalmics
  • Orphan disease
  • Pediatrics
  • Psychiatry
  • Respiratory
  • Appendix 5 -Deal type definitions
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Diagnostic Imaging partnering since 2014
  • Figure 2: Active Diagnostic Imaging dealmaking activity- 2014 to 2020
  • Figure 3: Diagnostic Imaging partnering by deal type since 2014
  • Figure 4: Diagnostic Imaging partnering by disease type since 2014
  • Figure 5: Diagnostic Imaging deals with a headline value
  • Figure 6: Diagnostic Imaging deals with an upfront value
  • Figure 7: Diagnostic Imaging deals with a milestone value
  • Figure 8: Diagnostic Imaging deals with a royalty rate value
  • Figure 9: Top Diagnostic Imaging deals by value since 2014
  • Figure 10: Most active Diagnostic Imaging dealmakers 2014 to 2020
  • Figure 11: Online partnering resources
  • Figure 12: Forthcoming partnering events
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.